ReviewCureus2026
Non-invasive Evaluation of Myocardial Fibrosis Using T1 and T2 Mapping by Cardiac Magnetic Resonance Imaging.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial fibrosis is a common pathological substrate across a broad spectrum of cardiovascular diseases and represents a key determinant of adverse clinical outcomes, including heart failure progression, arrhythmias, and sudden cardiac death. It may present as focal replacement fibrosis, typically following myocardial infarction, or as diffuse interstitial fibrosis, more frequently observed in non-ischemic cardiomyopathies and pressure-overload conditions. At the cellular level, fibrosis is driven by fibroblast activation and differentiation into myofibroblasts, mediated by profibrotic signaling pathways and sustained extracellular matrix deposition. Inflammation and myocardial edema also play a critical role in initiating and amplifying fibrotic remodeling, linking acute injury to chronic structural changes. Cardiac magnetic resonance imaging has emerged as a reference non-invasive modality for myocardial tissue characterization. Parametric mapping techniques, including T1, T2, and extracellular volume fraction mapping, provide a quantitative and highly reproducible assessment of myocardial composition. Native T1 mapping and extracellular volume fraction allow sensitive detection and quantification of diffuse myocardial fibrosis and have demonstrated significant prognostic value across several cardiovascular conditions, while T2 mapping is particularly sensitive to myocardial edema and active inflammation, enabling differentiation between acute and chronic myocardial injury. When integrated, these techniques enable a comprehensive evaluation of the inflammation-fibrosis continuum. Clinically, T1 and T2 mapping have demonstrated substantial value across ischemic and non-ischemic heart diseases, valvular disorders, and infiltrative cardiomyopathies. These techniques contribute to improved risk stratification, prediction of adverse ventricular remodeling, guidance of therapeutic decision-making, and monitoring of treatment response. Compared with late gadolinium enhancement imaging, echocardiographic strain analysis, and circulating biomarkers, parametric mapping offers greater tissue specificity and quantitative characterization of myocardial remodeling, although its implementation requires specialized equipment and technical expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.